265 related articles for article (PubMed ID: 17408933)
21. Quantitative risk modelling for new pharmaceutical compounds.
Tang Z; Taylor MJ; Lisboa P; Dyas M
Drug Discov Today; 2005 Nov; 10(22):1520-6. PubMed ID: 16257374
[TBL] [Abstract][Full Text] [Related]
22. Intellectual property rights, standards and data exchange in systems biology: Reflections from the IP Expert Meeting at the University of Luxembourg, 8-9 October 2015, ERASysAPP - ERA-Net for Systems Biology Applications.
van Zimmeren E; Rutz B; Minssen T
Biotechnol J; 2016 Dec; 11(12):1477-1480. PubMed ID: 27966844
[TBL] [Abstract][Full Text] [Related]
23. Using exposure-response and biomarkers to streamline early drug development.
Venitz J
Ernst Schering Res Found Workshop; 2007; (59):47-63. PubMed ID: 17117714
[TBL] [Abstract][Full Text] [Related]
24. Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report.
Burgess DJ; Crommelin DJ; Hussain AS; Chen ML;
AAPS PharmSci; 2004 Mar; 6(1):E11. PubMed ID: 15198512
[TBL] [Abstract][Full Text] [Related]
25. Systems biology: an evolving approach in drug discovery and development.
Ho RL; Lieu CA
Drugs R D; 2008; 9(4):203-16. PubMed ID: 18588352
[TBL] [Abstract][Full Text] [Related]
26. [Biological markers: utilization in drug development and approval].
Gueyffier F; Dib M; Boissel JP
Therapie; 2001; 56(4):355-61. PubMed ID: 11677852
[TBL] [Abstract][Full Text] [Related]
27. Connecting the dots: role of standardization and technology sharing in biological simulation.
Ghosh S; Matsuoka Y; Kitano H
Drug Discov Today; 2010 Dec; 15(23-24):1024-31. PubMed ID: 20934535
[TBL] [Abstract][Full Text] [Related]
28. Systems biology, metabolic modelling and metabolomics in drug discovery and development.
Kell DB
Drug Discov Today; 2006 Dec; 11(23-24):1085-92. PubMed ID: 17129827
[TBL] [Abstract][Full Text] [Related]
29. Promises of biomarkers in drug development--a reality check.
Marrer E; Dieterle F
Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
[TBL] [Abstract][Full Text] [Related]
30. A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT.
Bown JL; Shovman M; Robertson P; Boiko A; Goltsov A; Mullen P; Harrison DJ
Oncotarget; 2017 May; 8(18):29657-29667. PubMed ID: 27302920
[TBL] [Abstract][Full Text] [Related]
31. Biosimulation software is changing research.
Ho RL; Bartsell LT
Biotechnol Annu Rev; 2004; 10():297-302. PubMed ID: 15504712
[TBL] [Abstract][Full Text] [Related]
32. Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet.
Helmlinger G; Al-Huniti N; Aksenov S; Peskov K; Hallow KM; Chu L; Boulton D; Eriksson U; Hamrén B; Lambert C; Masson E; Tomkinson H; Stanski D
Eur J Pharm Sci; 2017 Nov; 109S():S39-S46. PubMed ID: 28506868
[TBL] [Abstract][Full Text] [Related]
33. In silico prediction of clinical efficacy.
Michelson S; Sehgal A; Friedrich C
Curr Opin Biotechnol; 2006 Dec; 17(6):666-70. PubMed ID: 17046236
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
Colburn WA; Lee JW
Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
[TBL] [Abstract][Full Text] [Related]
35. Evolving the Role of Discovery-focused Pathologists and Comparative Scientists in the Pharmaceutical Industry.
Mohanan S; Maguire S; Klapwijk J; Adler R; Haworth R; Clements P
Toxicol Pathol; 2019 Feb; 47(2):121-128. PubMed ID: 30651043
[TBL] [Abstract][Full Text] [Related]
36. Predictive biosimulation and virtual patients in pharmaceutical R and D.
Bangs A
Stud Health Technol Inform; 2005; 111():37-42. PubMed ID: 15718695
[TBL] [Abstract][Full Text] [Related]
37. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
38. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery.
Fischer HP
Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773
[TBL] [Abstract][Full Text] [Related]
39. New safe medicines faster: A proposal for a key action within the European union's 6th framework programme.
Bjerrum OJ
Pharmacol Toxicol; 2000; 86 Suppl 1():23-6. PubMed ID: 10905750
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
